Abstract:BackgroundTumorigenicity represents a critical challenge in stem cell-based therapies requiring rigorous monitoring. Conventional approaches for tumorigenicity evaluation are based on animal models and have numerous limitations. Brain organoids, which recapitulate the structural and functional complexity of the human brain, have been widely used in neuroscience research. However, the capacity of brain organoids for tumorigenicity evaluation needs to be further elucidated.MethodsA cerebral organoid model produced from human pluripotent stem cells (hPSCs) was employed. Meanwhile, to enhance the detection sensitivity for potential tumorigenic cells, we created a glioblastoma-like organoid (GBM organoid) model from TP53-/-/PTEN-/- hPSCs to provide a tumor microenvironment for injected cells. Midbrain dopamine (mDA) cells from human embryonic stem cells were utilized as a cell therapy product. mDA cells, hPSCs, mDA cells spiked with hPSCs, and immature mDA cells were then injected into the brain organoids and NOD SCID mice. The injected cells within the brain organoids were characterized, and compared with those injected in vivo to evaluate the capability of the brain organoids for tumorigenicity evaluation. Single-cell RNA sequencing was performed to identify the differential gene expression between the cerebral organoids and the GBM organoids.ResultsBoth cerebral organoids and GBM organoids supported maturation of the injected mDA cells. The hPSCs and immature mDA cells injected in the GBM organoids showed a significantly higher proliferative capacity than those injected in the cerebral organoids and in NOD SCID mice. Furthermore, the spiked hPSCs were detectable in both the cerebral organoids and the GBM organoids. Notably, the GBM organoids demonstrated a superior capacity to enhance proliferation and pluripotency of spiked hPSCs compared to the cerebral organoids and the mouse model. Kyoto Encyclopedia of Genes and Genomes analysis revealed upregulation of tumor-related metabolic pathways and cytokines in the GBM organoids, suggesting that these factors underlie the high detection sensitivity for tumorigenicity evaluation.ConclusionsOur findings suggest that brain organoids could represent a novel and effective platform for evaluating the tumorigenic risk in stem cell-based therapies. Notably, the GBM organoids offer a superior platform that could complement or potentially replace traditional animal-based models for tumorigenicity evaluation.

Blood-tumor barrier organoids recapitulate glioblastoma microenvironment and enable high-throughput modeling of therapeutic delivery

Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier

Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids

Glioblastoma organoid technology: an emerging preclinical models for drug discovery

Organoid Models of Glioblastoma: Advances, Applications and Challenges

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

The Advancements of Organoids Push the Boundaries of Glioblastoma Research

A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening

Tmic-34. Infiltrative Behavior Of Patient-Derived Glioblastoma Cell Lines In Region-Specific Human Brain Organoids

A Dynamic in Vivo-Like Organotypic Blood-Brain Barrier Model to Probe Metastatic Brain Tumors

3D Brain Vascular Niche Model Captures Invasive Behavior and Gene Signatures of Glioblastoma

Modeling the Precise Interaction of Glioblastoma with Human Brain Region-Specific Organoids

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics

Spontaneous Glioblastoma Spheroid Infiltration of Early-Stage Cerebral Organoids Models Brain Tumor Invasion

Single-cell dissection of the human blood-brain barrier and glioma blood-tumor barrier

A Tumorigenicity Evaluation Platform for Cell Therapies Based on Brain Organoids

Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment

A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier-penetrant nanoparticles

Abstract P20: Unveiling the Influence of Tumor Microenvironment and Spatial Heterogeneity on Temozolomide Resistance in Glioblastoma using an Advanced Human in vitro Model of the Blood-brain Barrier and Glioblastoma

A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor Growth

Tmic-33. Microenvironment-Driven Changes In Glioblastoma Cell State Signatures Examined Using Region-Specific Human Brain Organoids